← All indications
Ocular Hypertension
A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.
Subtype terms (1)
More specific conditions that are subtypes of Ocular Hypertension in the MeSH hierarchy.
- Glaucoma
141 drugs (80 approved, 61 experimental)
Drugs by status
Approved for this indication (20)
Phase 4 trials (11)
Phase 3 trials (10)
Phase 2 trials (41)
Phase 1 trials (7)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (54)
- Pfizer
- Bp Consulting, Inc
- FinnMedi Oy
- Glaukos Corporation
- Laboratoires Thea
- Vistakon Pharmaceuticals
- Otsuka
- Dr. Anton Hommer
- DBYAN Medicine Professional Corporation
- University of Pittsburgh
- Cornerstone Health Care, PA
- Katholieke Universiteit Leuven
- Northwestern Ophthalmic Institute S.C.
- Ohio State University
- Ophthalmic Consultants Centres, Canada
- Ophthalmic Consultants of Long Island
- Stanford University
- University of Michigan
- University of Nebraska
- University of Parma
- University of Patras
- University of Tampere
- University of Thessaly
- University of Toronto
- Mayo Clinic
- Association for Innovation and Biomedical Research on Light and Image (AIBILI)
- Laval University
- University of California, San Diego
- University of Vienna
- S.V. Malayan Eye Center
- +24 more
Organization Involved with Phase 3 Indications (32)
- PPD
- Actavis
- Adapt Produtos Oftalmológicos Ltda.
- Perrigo
- Alfred E. Tiefenbacher (GmbH & Co. KG)
- Santen Inc.
- InnoPharma
- Laboratorios Sophia S.A de C.V.
- NicOx
- Ocular Therapeutix, Inc.
- Sun Pharmaceuticals
- Chong Kun Dang Pharmaceutical
- Nephron Pharmaceuticals Corporation
- Taejoon Pharm Co., Ltd.
- Semmelweis University
- Seoul National University
- Universidad Complutense de Madrid
- University of Oulu
- University of Tehran
- Xiamen University
- Moscow State University
- Inotek
- Medical University of Vienna
- Lee's Pharmaceutical
- SPARC
- EMS S/A
- University Mulitiprofile Hospital for Active Treatment Sv.Georgi, Bulgaria
- P. Stradina Clinical University Hospital, Latvia
- Charles University
- Johannes Gutenburg University
- +2 more
Organization Involved with Phase 2 Indications (32)
- Novelion Therapeutics
- Acucela Inc.
- Bausch Health Companies
- Roche
- AstraZeneca
- Alleanza Pharmaceuticals, Inc.
- Aerpio Therapeutics
- American Society Of Thermalism And Climatology Inc
- Can-Fite BioPharma
- Lexicon Pharmaceuticals
- Mati Therapeutics Inc.
- Othera Pharmaceuticals
- Peregrine Ophthalmic
- Altheos, Inc.
- Amakem, NV
- Envisia Therapeutics
- PharmaMar
- BioLight
- Glaucoma Associates of New York
- Singapore Eye Research Institute
- Singapore National Eye Centre
- University of California, Davis
- ForSight Vision 5
- America Society of thermalism
- Clinica Universidad de Navarra
- Danube Pharmaceuticals
- Catholic University of Sacred Heart, Rome
- Ono Pharmaceuticals
- Future Medicine Ltd.
- Ocuphire Pharma, Inc.
- +2 more
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (17)
- Aurolab
- Chakshu Research, Inc.
- United States Army
- Hermann Eye Center
- McMaster University
- Philadelphia Eye Associates
- The New York Eye & Ear Infirmary
- Peking University
- Tel Aviv University
- University of Colorado, Denver
- Icahn School of Medicine at Mount Sinai
- Hebrew University
- Sun Yat-Sen University
- University of Texas at Houston
- Aravind Eye Hospital
- Gsap Medical Ltd.
- Eximore Ltd.